Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

医学 免疫原性 接种疫苗 耐受性 菌斑减少中和试验 α病毒 病毒学 不利影响 免疫学 内科学 免疫系统 中和抗体 病毒
作者
Emily E. Coates,Srilatha Edupuganti,Grace Chen,Myra Happe,Larisa Strom,Alicia T. Widge,Maria Burgos Florez,Josephine H. Cox,Ingelise J. Gordon,Sarah H. Plummer,Abidemi Ola,Galina V. Yamshchikov,Charla Andrews,Sharon Curate-Ingram,Patricia Morgan,Shashi Nagar,Matthew H. Collins,Amy Bray,Thuy Nguyen,Judy Stein,Christopher L. Case,Florence Kaltovich,Diane Wycuff,Chen Liang,Kevin Carlton,Sandra Vazquez,John R. Mascola,Julie E. Ledgerwood,Ellie Butler,Jean M. Winter,Jianguo Xu,Amy Sherman,Colleen F. Kelley,Rameses Fredrick,Nadine Rouphael,Varun K. Phadke,Cynthia G. Whitney,Alicarmen Alvarez,Renata Dennis,Rebecca Fineman,Pamela Lankford-Turner,Sha Yi,Lilin Lai,Gena Burch,Shanker Gupta,Nina M. Berkowitz,Cristina Carter,Allison Beck,Brenda Larkin,Stephanie Taylor,Mandy Alger,Jessica Bahorich,Amy L. Chamberlain,Ya-Chen Chang,Rajoshi Chaudhuri,Jonathan W. Cooper,Jacob Demirji,Fan Yang,Alissa Fernald,Deepika Gollapudi,Janel Holland-Linn,Lisa A. Kueltzo,James Lee,Jie Liu,Xun Liu,Rachel Mowery,Sarah O’Connell,Erwin Rosales‐Zavala,J. S. Sands,Xin Wang,Shaojie Weng,Sara Witter
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:22 (8): 1210-1220 被引量:21
标识
DOI:10.1016/s1473-3099(22)00052-4
摘要

Background Western (WEEV), eastern (EEEV), and Venezuelan (VEEV) equine encephalitis viruses are mosquito-borne pathogens classified as potential biological warfare agents for which there are currently no approved human vaccines or therapies. We aimed to evaluate the safety, tolerability, and immunogenicity of an investigational trivalent virus-like particle (VLP) vaccine, western, eastern, and Venezuelan equine encephalitis (WEVEE) VLP, composed of WEEV, EEEV, and VEEV VLPs. Methods The WEVEE VLP vaccine was evaluated in a phase 1, randomised, open-label, dose-escalation trial at the Hope Clinic of the Emory Vaccine Center at Emory University, Atlanta, GA, USA. Eligible participants were healthy adults aged 18–50 years with no previous vaccination history with an investigational alphavirus vaccine. Participants were assigned to a dose group of 6 μg, 30 μg, or 60 μg vaccine product and were randomly assigned (1:1) to receive the WEVEE VLP vaccine with or without aluminium hydroxide suspension (alum) adjuvant by intramuscular injection at study day 0 and at week 8. The primary outcomes were the safety and tolerability of the vaccine (assessed in all participants who received at least one administration of study product) and the secondary outcome was immune response measured as neutralising titres by plaque reduction neutralisation test (PRNT) 4 weeks after the second vaccination. This trial is registered at ClinicalTrials.gov, NCT03879603. Findings Between April 2, 2019, and June 13, 2019, 30 trial participants were enrolled (mean age 32 years, range 21–48; 16 [53%] female participants and 14 [47%] male participants). Six groups of five participants each received 6 μg, 30 μg, or 60 μg vaccine doses with or without adjuvant, and all 30 participants completed study follow-up. Vaccinations were safe and well tolerated. The most frequently reported symptoms were mild injection-site pain and tenderness (22 [73%] of 30) and malaise (15 [50%] of 30). Dose-dependent differences in the frequency of pain and tenderness were found between the 6 μg, 30 μg, and 60 μg groups (p=0·0217). No significant differences were observed between dosing groups for any other reactogenicity symptom. Two adverse events (mild elevated blood pressure and moderate asymptomatic neutropenia) were assessed as possibly related to the study product in one trial participant (60 μg dose with alum); both resolved without clinical sequelae. 4 weeks after second vaccine administration, neutralising antibodies were induced in all study groups with the highest response seen against all three vaccine antigens in the 30 μg plus alum group (PRNT80 geometric mean titre for EEEV 60·8, 95% CI 29·9–124·0; for VEEV 111·5, 49·8–249·8; and for WEEV 187·9, 90·0–392·2). Finally, 4 weeks after second vaccine administration, for all doses, the majority of trial participants developed an immune response to all three vaccine components (24 [83%] of 29 for EEEV; 26 [90%] of 29 for VEEV; 27 [93%] of 29 for WEEV; and 22 [76%] of 29 for EEEV, VEEV, and WEEV combined). Interpretation The favourable safety profile and neutralising antibody responses, along with pressing public health need, support further evaluation of the WEVEE VLP vaccine in advanced-phase clinical trials. Funding The Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, National Institutes of Health funded the clinical trial. The US Department of Defense contributed funding for manufacturing of the study product.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
活泼雪莲发布了新的文献求助10
刚刚
可乐大侠完成签到 ,获得积分10
刚刚
萌萌2完成签到,获得积分10
刚刚
慈祥的鸿煊完成签到 ,获得积分10
1秒前
fantasy的应助被369ninja采纳,获得10
2秒前
王不凡完成签到 ,获得积分10
2秒前
Jeffrey完成签到,获得积分10
2秒前
蝈蝈完成签到,获得积分10
3秒前
雪山大地发布了新的文献求助10
4秒前
Echo完成签到,获得积分0
7秒前
JIANG完成签到,获得积分10
9秒前
ARIA完成签到 ,获得积分0
9秒前
群山完成签到 ,获得积分10
10秒前
mongmong完成签到 ,获得积分10
11秒前
12秒前
春夏完成签到 ,获得积分10
12秒前
卢彦冬完成签到,获得积分10
14秒前
15秒前
冷静以山完成签到 ,获得积分10
19秒前
飞儿完成签到 ,获得积分10
21秒前
369ninja发布了新的文献求助10
21秒前
兴奋的惮完成签到,获得积分10
22秒前
进击的牛马完成签到,获得积分10
22秒前
游01完成签到 ,获得积分10
24秒前
打打的应助被活泼雪莲采纳,获得10
26秒前
zhuangbaobao完成签到,获得积分10
26秒前
27秒前
个性怡完成签到 ,获得积分10
27秒前
深情的乐萱完成签到,获得积分10
27秒前
雪山大地发布了新的文献求助10
29秒前
失眠的寄云完成签到,获得积分10
32秒前
32秒前
O_0完成签到 ,获得积分10
32秒前
WQ完成签到,获得积分10
32秒前
莹莹大王发布了新的文献求助10
37秒前
落月无痕完成签到,获得积分10
39秒前
win050532完成签到 ,获得积分10
40秒前
吃饭打肯德基完成签到 ,获得积分10
42秒前
马伯乐完成签到 ,获得积分10
44秒前
Qinzhiyuan1990完成签到 ,获得积分10
44秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166550
求助须知:如何正确求助?哪些是违规求助? 9559535
关于积分的说明 21750720
捐赠科研通 7757357
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553523
邀请新用户注册赠送积分活动 2473904